1.
|
Details of PDMR/person closely associated with them
('PCA')
|
||||
a)
|
Name
|
Ms E Walmsley
|
|||
b)
|
Position/status
|
Chief Executive Officer
|
|||
c)
|
Initial
notification/amendment
|
Initial notification
|
|||
2.
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
||||
a)
|
Name
|
GlaxoSmithKline plc
|
|||
b)
|
LEI
|
5493000HZTVUYLO1D793
|
|||
3.
|
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted
|
||||
a)
|
Description
of the financial instrument
|
Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882
|
|||
b)
|
Nature
of the transaction
|
Increase in notional interest in Ordinary Shares following the
re-investment of dividends paid to shareholders on 9 January 2020
on Ordinary Shares held in the Company's Deferred Annual Bonus
Plan.
|
|||
c)
|
Price(s)
and volume(s)
|
|
Price(s)
|
Volume(s)
|
|
|
£17.9020
|
195
|
|
||
|
£17.9020
|
195
|
|
||
|
£17.9020
|
684
|
|
||
|
£17.9020
|
680
|
|
||
|
|
|
|
||
d)
|
Aggregated
information
|
1,754
|
|||
Aggregated
volume
Price
|
£17.9020
|
||||
e)
|
Date
of the transaction
|
2020-01-13
|
|||
f)
|
Place
of the transaction
|
London Stock Exchange (XLON)
|
1.
|
Details of PDMR/person closely associated with them
('PCA')
|
||||
a)
|
Name
|
Mr R Connor
|
|||
b)
|
Position/status
|
President, Global Vaccines
|
|||
c)
|
Initial
notification/amendment
|
Initial notification
|
|||
2.
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
||||
a)
|
Name
|
GlaxoSmithKline plc
|
|||
b)
|
LEI
|
5493000HZTVUYLO1D793
|
|||
3.
|
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted
|
||||
a)
|
Description
of the financial instrument
|
Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882
|
|||
b)
|
Nature
of the transaction
|
Increase in notional interest in Ordinary Shares following the
re-investment of dividends paid to shareholders on 9 January 2020
on Ordinary Shares held in the Company's Deferred Annual Bonus
Plan.
|
|||
c)
|
Price(s)
and volume(s)
|
|
Price(s)
|
Volume(s)
|
|
|
£17.9020
|
101
|
|
||
|
£17.9020
|
101
|
|
||
|
£17.9020
|
144
|
|
||
|
£17.9020
|
178
|
|
||
|
|
|
|
||
d)
|
Aggregated
information
|
524
|
|||
Aggregated
volume
Price
|
£17.9020
|
||||
e)
|
Date
of the transaction
|
2020-01-13
|
|||
f)
|
Place
of the transaction
|
London Stock Exchange (XLON)
|
1.
|
Details of PDMR/person closely associated with them
('PCA')
|
||||
a)
|
Name
|
Mr N Hirons
|
|||
b)
|
Position/status
|
SVP, Global Ethics & Compliance
|
|||
c)
|
Initial
notification/amendment
|
Initial notification
|
|||
2.
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
||||
a)
|
Name
|
GlaxoSmithKline plc
|
|||
b)
|
LEI
|
5493000HZTVUYLO1D793
|
|||
3.
|
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted
|
||||
a)
|
Description
of the financial instrument
|
Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882
|
|||
b)
|
Nature
of the transaction
|
Increase in notional interest in Ordinary Shares following the
re-investment of dividends paid to shareholders on 9 January 2020
on Ordinary Shares held in the Company's Deferred Annual Bonus
Plan.
|
|||
c)
|
Price(s)
and volume(s)
|
|
Price(s)
|
Volume(s)
|
|
|
£17.9020
|
64
|
|
||
|
£17.9020
|
64
|
|
||
|
£17.9020
|
75
|
|
||
|
£17.9020
|
74
|
|
||
|
|
|
|
||
d)
|
Aggregated
information
|
277
|
|||
Aggregated
volume
Price
|
£17.9020
|
||||
e)
|
Date
of the transaction
|
2020-01-13
|
|||
f)
|
Place
of the transaction
|
London Stock Exchange (XLON)
|
1.
|
Details of PDMR/person closely associated with them
('PCA')
|
||||
a)
|
Name
|
Mr L Miels
|
|||
b)
|
Position/status
|
President, Global Pharmaceuticals
|
|||
c)
|
Initial
notification/amendment
|
Initial notification
|
|||
2.
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
||||
a)
|
Name
|
GlaxoSmithKline plc
|
|||
b)
|
LEI
|
5493000HZTVUYLO1D793
|
|||
3.
|
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted
|
||||
a)
|
Description
of the financial instrument
|
Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882
|
|||
b)
|
Nature
of the transaction
|
Increase in notional interest in Ordinary Shares following the
re-investment of dividends paid to shareholders on 9 January 2020
on Ordinary Shares held in the Company's Deferred Annual Bonus
Plan.
|
|||
c)
|
Price(s)
and volume(s)
|
|
Price(s)
|
Volume(s)
|
|
|
£17.9020
|
137
|
|
||
|
£17.9020
|
190
|
|
||
|
|
|
|
||
d)
|
Aggregated
information
|
327
|
|||
Aggregated
volume
Price
|
£17.9020
|
||||
e)
|
Date
of the transaction
|
2020-01-13
|
|||
f)
|
Place
of the transaction
|
London Stock Exchange (XLON)
|
1.
|
Details of PDMR/person closely associated with them
('PCA')
|
||||
a)
|
Name
|
Mr D Redfern
|
|||
b)
|
Position/status
|
Chief Strategy Officer
|
|||
c)
|
Initial
notification/amendment
|
Initial notification
|
|||
2.
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
||||
a)
|
Name
|
GlaxoSmithKline plc
|
|||
b)
|
LEI
|
5493000HZTVUYLO1D793
|
|||
3.
|
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted
|
||||
a)
|
Description
of the financial instrument
|
Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882
|
|||
b)
|
Nature
of the transaction
|
Increase in notional interest in Ordinary Shares following the
re-investment of dividends paid to shareholders on 9 January 2020
on Ordinary Shares held in the Company's Deferred Annual Bonus
Plan.
|
|||
c)
|
Price(s)
and volume(s)
|
|
Price(s)
|
Volume(s)
|
|
|
£17.9020
|
80
|
|
||
|
£17.9020
|
80
|
|
||
|
£17.9020
|
140
|
|
||
|
£17.9020
|
168
|
|
||
|
|
|
|
||
d)
|
Aggregated
information
|
468
|
|||
Aggregated
volume
Price
|
£17.9020
|
||||
e)
|
Date
of the transaction
|
2020-01-13
|
|||
f)
|
Place
of the transaction
|
London Stock Exchange (XLON)
|
1.
|
Details of PDMR/person closely associated with them
('PCA')
|
||||
a)
|
Name
|
Mr R Simard
|
|||
b)
|
Position/status
|
President, Pharmaceuticals Supply Chain
|
|||
c)
|
Initial
notification/amendment
|
Initial notification
|
|||
2.
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
||||
a)
|
Name
|
GlaxoSmithKline plc
|
|||
b)
|
LEI
|
5493000HZTVUYLO1D793
|
|||
3.
|
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted
|
||||
a)
|
Description
of the financial instrument
|
Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882
|
|||
b)
|
Nature
of the transaction
|
Increase in notional interest in Ordinary Shares following the
re-investment of dividends paid to shareholders on 9 January 2020
on Ordinary Shares held in the Company's Deferred Annual Bonus
Plan.
|
|||
c)
|
Price(s)
and volume(s)
|
|
Price(s)
|
Volume(s)
|
|
|
£17.9020
|
61
|
|
||
|
|
|
|
||
d)
|
Aggregated
information
|
N/A (single transaction)
|
|||
Aggregated
volume
Price
|
|
||||
e)
|
Date
of the transaction
|
2020-01-13
|
|||
f)
|
Place
of the transaction
|
London Stock Exchange (XLON)
|
1.
|
Details of PDMR/person closely associated with them
('PCA')
|
||||
a)
|
Name
|
Mr P Thomson
|
|||
b)
|
Position/status
|
President, Global Affairs
|
|||
c)
|
Initial
notification/amendment
|
Initial notification
|
|||
2.
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
||||
a)
|
Name
|
GlaxoSmithKline plc
|
|||
b)
|
LEI
|
5493000HZTVUYLO1D793
|
|||
3.
|
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted
|
||||
a)
|
Description
of the financial instrument
|
Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882
|
|||
b)
|
Nature
of the transaction
|
Increase in notional interest in Ordinary Shares following the
re-investment of dividends paid to shareholders on 9 January 2020
on Ordinary Shares held in the Company's Deferred Annual Bonus
Plan.
|
|||
c)
|
Price(s)
and volume(s)
|
|
Price(s)
|
Volume(s)
|
|
|
£17.9020
|
76
|
|
||
|
£17.9020
|
95
|
|
||
|
£17.9020
|
98
|
|
||
|
|
|
|
||
d)
|
Aggregated
information
|
269
|
|||
Aggregated
volume
Price
|
£17.9020
|
||||
e)
|
Date
of the transaction
|
2020-01-13
|
|||
f)
|
Place
of the transaction
|
London Stock Exchange (XLON)
|
1.
|
Details of PDMR/person closely associated with them
('PCA')
|
||||
a)
|
Name
|
Mr B McNamara
|
|||
b)
|
Position/status
|
CEO, GSK Consumer Healthcare
|
|||
c)
|
Initial
notification/amendment
|
Initial notification
|
|||
2.
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
||||
a)
|
Name
|
GlaxoSmithKline plc
|
|||
b)
|
LEI
|
5493000HZTVUYLO1D793
|
|||
3.
|
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted
|
||||
a)
|
Description
of the financial instrument
|
American Depositary Shares ('ADSs')
ISIN: US37733W1053
|
|||
b)
|
Nature
of the transaction
|
Increase in notional interest in ADSs following the re-investment
of dividends paid to shareholders on 9 January 2020 on ADSs held in
the Company's Deferred Annual Bonus Plan.
|
|||
c)
|
Price(s)
and volume(s)
|
|
Price(s)
|
Volume(s)
|
|
|
$46.6500
|
74
|
|
||
|
$46.6500
|
72
|
|
||
|
$46.6500
|
68
|
|
||
|
|
|
|
||
|
|
|
|
||
d)
|
Aggregated
information
|
214
|
|||
Aggregated
volume
Price
|
$46.6500
|
||||
e)
|
Date
of the transaction
|
2020-01-13
|
|||
f)
|
Place
of the transaction
|
New York Stock Exchange (XNYS)
|
1.
|
Details of PDMR/person closely associated with them
('PCA')
|
||||
a)
|
Name
|
Dr H Barron
|
|||
b)
|
Position/status
|
Chief Scientific Officer and President, R&D
|
|||
c)
|
Initial
notification/amendment
|
Initial notification
|
|||
2.
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
||||
a)
|
Name
|
GlaxoSmithKline plc
|
|||
b)
|
LEI
|
5493000HZTVUYLO1D793
|
|||
3.
|
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted
|
||||
a)
|
Description
of the financial instrument
|
American Depositary Shares ('ADSs')
ISIN: US37733W1053
|
|||
b)
|
Nature
of the transaction
|
Increase in notional interest in ADSs following the re-investment
of dividends paid to shareholders on 9 January 2020 on ADSs held in
the Company's Deferred Annual Bonus Plan.
|
|||
c)
|
Price(s)
and volume(s)
|
|
Price(s)
|
Volume(s)
|
|
|
$46.6500
|
406
|
|
||
|
|
|
|
||
d)
|
Aggregated
information
|
N/A (single transaction)
|
|||
Aggregated
volume
Price
|
|
||||
e)
|
Date
of the transaction
|
2020-01-13
|
|||
f)
|
Place
of the transaction
|
New York Stock Exchange (XNYS)
|
1.
|
Details of PDMR/person closely associated with them
('PCA')
|
||||
a)
|
Name
|
Mr J Ford
|
|||
b)
|
Position/status
|
Senior Vice President and General Counsel
|
|||
c)
|
Initial
notification/amendment
|
Initial notification
|
|||
2.
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
||||
a)
|
Name
|
GlaxoSmithKline plc
|
|||
b)
|
LEI
|
5493000HZTVUYLO1D793
|
|||
3.
|
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted
|
||||
a)
|
Description
of the financial instrument
|
American Depositary Shares ('ADSs')
ISIN: US37733W1053
|
|||
b)
|
Nature
of the transaction
|
Increase in notional interest in ADSs following the re-investment
of dividends paid to shareholders on 9 January 2020 on ADSs held in
the Company's Deferred Annual Bonus Plan.
|
|||
c)
|
Price(s)
and volume(s)
|
|
Price(s)
|
Volume(s)
|
|
|
$46.6500
|
35
|
|
||
|
|
|
|
||
d)
|
Aggregated
information
|
N/A (single transaction)
|
|||
Aggregated
volume
Price
|
|
||||
e)
|
Date
of the transaction
|
2020-01-13
|
|||
f)
|
Place
of the transaction
|
New York Stock Exchange (XNYS)
|
1.
|
Details of PDMR/person closely associated with them
('PCA')
|
||||
a)
|
Name
|
Ms K Terrell
|
|||
b)
|
Position/status
|
Chief Digital & Technology Officer
|
|||
c)
|
Initial
notification/amendment
|
Initial notification
|
|||
2.
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
||||
a)
|
Name
|
GlaxoSmithKline plc
|
|||
b)
|
LEI
|
5493000HZTVUYLO1D793
|
|||
3.
|
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted
|
||||
a)
|
Description
of the financial instrument
|
American Depositary Shares ('ADSs')
ISIN: US37733W1053
|
|||
b)
|
Nature
of the transaction
|
Increase in notional interest in ADSs following the re-investment
of dividends paid to shareholders on 9 January 2020 on ADSs held in
the Company's Deferred Annual Bonus Plan.
|
|||
c)
|
Price(s)
and volume(s)
|
|
Price(s)
|
Volume(s)
|
|
|
$46.6500
|
24
|
|
||
|
$46.6500
|
86
|
|
||
|
|
|
|
||
d)
|
Aggregated
information
|
110
|
|||
Aggregated
volume
Price
|
$46.6500
|
||||
e)
|
Date
of the transaction
|
2020-01-13
|
|||
f)
|
Place
of the transaction
|
New York Stock Exchange (XNYS)
|
|
GlaxoSmithKline plc
|
|
(Registrant)
|
|
|
Date: January
15, 2020
|
|
|
|
|
By:/s/ VICTORIA
WHYTE
--------------------------
|
|
|
|
Victoria Whyte
|
|
Authorised
Signatory for and on
|
|
behalf
of GlaxoSmithKline plc
|